Physician profile
Tanvi Patel
NPI 1467039818
$6,150.45
in general payments reported to CMS, 2019-2025
32 companies · $2,168 in 2025
The $2,168 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $500 · 2023: $1,654 · 2024: $1,645 · 2025: $2,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,433 · Education: $34.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,432.95 |
| Education | $34.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.50 | 2022-2025 | |
| Janssen Biotech, INC. | $898.47 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $701.87 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $700.03 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $347.46 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $314.69 | 2022-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $256.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Astrazeneca Pharmaceuticals LP | $226.57 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $207.93 | 2022-2024 | Ocaliva |
| Ardelyx, INC. | $199.78 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $182.51 | 2023-2024 | Rebyota |
| Novo Nordisk INC | $178.80 | 2022-2025 | Wegovy |
| Daiichi Sankyo INC. | $142.38 | 2023-2025 | Injectafer |
| Genzyme Corporation | $128.30 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $122.54 | 2024-2025 | Zenpep |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $82.46 | 2024 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $71.89 | 2022-2024 | Dificid |
| Amgen INC. | $33.96 | 2022-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $31.29 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $30.82 | 2025 | Voquezna |
| Evoke Pharma, INC. | $29.30 | 2023-2025 | Gimoti |
| Organon LLC | $27.25 | 2023 | Hadlima |
| Exact Sciences Corporation | $26.77 | 2025 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $25.01 | 2025 | Givlaari |
| Inspire Medical Systems, INC. | $19.48 | 2024 | Inspire |
| Lilly USA, LLC | $18.31 | 2024 | Omvoh |
| W. L. Gore & Associates, INC. | $17.49 | 2023 | Gore Cardioform Septal Occluder |
| Gilead Sciences, INC. | $15.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2021 | |
| Orphalan INC | $14.12 | 2024 | Cuvrior |
| Mylan Specialty L.P. | $13.28 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanvi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.